Email This

Deciphering Best Practices for Monitoring Patients With CML and Ph+ ALL CME

Jerald P. Radich, MD Author Information and Disclosures

Release Date: February 27, 2008; Valid for credit through February 27, 2009

Credits Available

Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

This CME activity is based on transcripts and slides of presentations as delivered by faculty at the "Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors: Clinical Considerations and Interactive Case Studies" symposium held at the Georgia World Congress Center in Atlanta, Georgia, on December 7, 2007.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Deciphering Best Practices for Monitoring Patients With CML and Ph+ ALL
Jerald P. Radich, MD

Go to CME Test Questions

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

Evaluate the different methods used to measure response in patients with CML being treated with tyrosine kinase inhibitor (TKI) therapy;
Discuss the treatment milestones, appropriate timing and frequency for measurement of hematologic, cytogenetic, and molecular responses for patients with CML;
Identify patients receiving TKIs who are achieving a suboptimal response;
Describe the appropriate timing for the evaluation of the BCR-ABL mutation status in patients with resistant CML.

Author Disclosures

Jerald P. Radich, MD
Disclosure: Grants/Research Support: Bristol-Myers Squibb Company, Novartis Pharmaceuticals. Consultant: Bristol-Myers Squibb Company; Merck & Co., Inc.; Novartis Pharmaceuticals.

SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SciMed designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider